Search results
HsCRP in ASCVD
Author(s):
Adhya Mehta
,
Roger S Blumenthal
,
Ty J Gluckman
,
et al
Added:
11 months ago
Review Article
Author(s):
Paul M Ridker
Added:
2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The…
View more
Ramzi Y. J. Khamis
Job title: Professor of Cardiology, Wu Family Endowed Chair of Cardiology, Consultant Interventional Cardiologist
Author
Author(s):
Matthias Bossard
Added:
4 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Author(s):
Deitrich Gerlt
,
Sharon Mathai
,
Kristopher Aten
,
et al
Added:
1 year ago
Author(s):
Erin A Bohula
,
Harriette Van Spall
Added:
3 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
Author(s):
Evan A Stein
Added:
1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period…
View more
Author(s):
Joo-Yong Hahn
Added:
11 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
ESC 25: The HI-PRO Trial
Author(s):
Gregory Piazza
Added:
6 months ago
Video
Author(s):
John Hummel
Added:
2 years ago
AHA 2023 — In this short interview, we are joined by Dr John Hummel (Ohio State University, US) to discuss the findings from the JEWEL-IDE (NCT05201495) study, which investigated the use of the Jewel patch-wearable cardioverter defibrillator (PWCD) system in participants who were at high risk for sudden cardiac arrest. This was a multicenter, prospective, single-arm trial, with 290 participants…
View more